American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment OptionsLowell E. Schnipper, Richard L. Schilsky, J. Russell Hoverman et al.|Journal of Clinical Oncology|2015Cited by 903
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal CancerAlan P. Venook, Charles D. Blanke, Donna Niedzwiecki et al.|JAMA|2017Cited by 891
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments ReceivedLowell E. Schnipper, Richard L. Schilsky, Nancy E. Davidson et al.|Journal of Clinical Oncology|2016Cited by 654
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical TrialBert H. O’Neil, Richard M. Goldberg, Monica M. Bertagnolli et al.|UNC Libraries|2020Cited by 96